Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update
Rhea-AI Summary
Wellgistics Health (NASDAQ:WGRX) reported Q1 2026 results and a business update. Wellgistics Pharmacy monthly revenue rose from about $0.1M in November 2025 to $0.6M in April 2026. Sequential revenue increased from $0.486M in Q4 2025 to $0.929M in Q1 2026, with Q2 2026 revenue projected at $1.775M.
The company completed a Kare Pharmtech joint venture, gaining telepharmacy access to 200,000+ patient lives, and expanded its Tollo Health partnership, targeting an August 2026 “Health Lives Here” app launch with NFL Alumni Health. Net operating loss narrowed to $7.742M from $32.430M year over year.
Positive
- Sequential revenue growth from $0.486M in Q4 2025 to $0.929M in Q1 2026
- Q2 2026 revenue projected at $1.775M, with $0.86M recognized through May 18, 2026
- Wellgistics Pharmacy monthly revenue increased from ~$0.1M to ~$0.6M between November 2025 and April 2026
- Net operating loss reduced to $7.742M from $32.430M year over year
- Completed Kare Pharmtech joint venture, adding telepharmacy and access to 200,000+ patient lives
- Expanded Tollo Health partnership with app, medical foods, and NFL Alumni Health marketing
Negative
- Net operating loss remained $7.742M for the quarter ended March 30, 2026
- Net loss per share of $0.07 on 104.6M weighted average shares versus $0.62 on 51.916M shares, indicating dilution
- Previously announced non-binding letters of intent with Neuritek and WellCare were terminated
- Discussions to expand the Datavault AI PharmacyChain license remain pending, not yet finalized
News Market Reaction – WGRX
In the May 20 session, WGRX declined 23.21%, reflecting a significant negative market reaction. Argus tracked a peak move of +42.8% during that session. Argus tracked a trough of -45.2% from its starting point during tracking. Our momentum scanner triggered 46 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 20 | Quarterly earnings update | Negative | -15.6% | Reported sharply higher net operating loss and wider per-share loss versus prior year. |
| May 12 | Quarterly earnings update | Positive | -5.5% | Announced 36% revenue growth to $10.86M and strong pharmacy onboarding metrics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have previously led to negative moves, including selloffs after both weak results and a prior quarter of strong revenue growth, indicating a tendency for cautious market reactions around financial updates.
Recent earnings history for Wellgistics shows challenging fundamentals and cautious market responses. On May 12, 2025, the company reported Q1 2025 revenue of $10.86M with 36% year-over-year growth, yet the stock fell 5.54%. On November 20, 2025, Q3 2025 results included a $33.878M net operating loss and $0.46 loss per share on 74.379M shares, followed by a 15.6% decline. Today’s Q1 2026 update, with pharmacy ramp and cost cuts, follows this pattern of material but high-risk financial disclosures.
Key Terms
telepharmacy medical
telemedicine medical
glp-1 medical
health-as-a-service (haas) technical
hipaa-compliant regulatory
smart contract technical
blockchain technical
quantum key encryption technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Wellgistics Pharmacy monthly revenue increased from approximately
$0.1 million in November 2025 to approximately$0.6 million in April 2026, based on preliminary unaudited resultsQ1-26 focus on optimization of Wellgistics Pharmacy revenue growth and capabilities positions Company to integrate emerging licensed PharmacyChain™ pharmacy data tokenization technology into pharmacy dispensing AI hub EinsteinRx™
Kare Pharmtech joint venture expands the Company's telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient lives
Strategic partnership with Tollo Health provides access to proprietary pharmaceutical-adjunct medical foods & dietary supplements, telemedicine and mental health AI coaching & regimen compliance tools via "Health Lives Here" app that is targeted to launch in August 2026 following the reveal with NFL Alumni Health at 2026 NFL Draft in Pittsburgh
The Company is in advanced discussions with Datavault AI regarding a binding term sheet to expand the scope of the PharmacyChain™ license to include Health-as-a-Service (HaaS) capabilities
Company has terminated previously announced non-binding letters of intent with Neuritek and WellCare and does not intend to proceed with those transactions
TAMPA, FL / ACCESS Newswire / May 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology company, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ with licensed blockchain-enabled smart contract technology through PharmacyChain™, reported financial results for the first quarter ended March 31, 2026 and provided a second quarter 2026 business update from its President & Interim-CEO Prashant Patel, RPh.
"The Company's first quarter focus on expanding direct sales from its Wellgistics Pharmacy segment led to sequential quarter over quarter growth that is now beginning to reach critical mass in the second quarter," said Prashant Patel, RPh, President & Interim-CEO Prashant Patel. "We believe the sequential growth in Wellgistics Pharmacy revenue, together with our Kare Pharmtech joint venture, provides a foundation for continued expansion of our direct-to-patient initiatives. As we work to onboard patient lives available through the joint venture and prepare for the targeted August 2026 launch of the Health Lives Here initiative with Tollo Health and NFL Alumni Health, we are also continuing to advance the integration of PharmacyChain™ functionality with our EinsteinRx™ pharmacy dispensing AI hub. As we onboard an increasing percentage of the 200,000+ patient lives through the joint venture, we are preparing to support a significant ramp up in prescription dispending through our direct-to-consumer initiatives with Tollo Health coming from that planned August 2026 launch through the partnership with NFL Alumni Health of the "Health Lives Here initiative" that was revealed at the 2026 NFL Draft in Pittsburgh."
Mr. Patel continued, "As we engage with stakeholders in the pharmaceutical distribution space, we believe the GLP-1 market remains in an early stage of development and that products such as the Forzet™ medical food product, which is intended to support the dietary management of muscle loss associated with weight-loss therapies may represent an important adjunct opportunity," We intend to increasingly focus on the GLP-1 segment and consolidate the capabilities required to provide what we believe to be a seamless end-to-end user experience that will likely lead to strong customer satisfaction and retention."
"We believe the cost reduction and operating discipline implemented by management have better aligned the Company's expense structure with its near-term revenue opportunities," noted Mr. Patel.
First Quarter 2026 Corporate Highlights
Sequential quarter over quarter revenue growth:
Q4-2025:
$0.486 million Q1-2026:
$0.929 million Q2-2026: The Company expects revenue of
$1.775 million (projected,$0.86M already recognized through May 18, 2026)
Added quantum key encryption functionality to the Datavault AI PharmacyChain™ license to enhance security features for the Company's emerging pharmaceutical distribution-focused blockchain platform Tollo Health partnership expansion adds telehealth, mental health AI coaching & regimen compliance tools via proprietary app, proprietary medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies, and NFL Alumni Health's "Health Lives Here" marketing partnership to Wellgistics capabilities
Insurance Eligibility and benefits verification (EBV) services added to EinsteinRx offering
Continued strategic shift focusing on direct-to-consumer market
Second Quarter 2026 Corporate Highlights to Date and Upcoming Milestones
Progress to date
Completed joint venture with KareRx to add KareRx technology hub and operations to EinsteinEx, gaining telepharmacy capabilities and operations in order to position for increasing Wellgistics Pharmacy dispensing activities, onboarding of new manufacturer relationships and execution of the pending "Health Lives Here" app launch targeted for August 2026 in partnership with NFL Alumni Health
Pending milestones
Continue discussions with Datavault AI regarding an expansion of the PharmacyChain™ license to include Health-as-a-Service capabilities Establish initial HIPAA-compliant data transfer functionality designed to support smart contract-enabled prescription drug transactions through Wellgistics Pharmacy
Loss from Operations:
The Company recorded a net operating loss of
This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Wellgistics Health, Inc.
Wellgistics Health (NASDAQ:WGRX), is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected second quarter 2026 revenue, expected growth of Wellgistics Pharmacy revenue, the anticipated benefits of the Kare Pharmtech joint venture, the anticipated onboarding of patient lives, the targeted August 2026 launch of the Health Lives Here app, the anticipated benefits of the Tollo Health partnership, the Company's plans regarding GLP-1 related opportunities, the integration of PharmacyChain™ functionality with EinsteinRx™, the potential expansion of the Datavault AI PharmacyChain™ license to include Health-as-a-Service capabilities, the expected development of HIPAA-compliant data transfer functionality, and the Company's expectations regarding its business strategy, operating discipline, revenue opportunities and future growth. Forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "target," "may," "will," "would," "could," "should," "seek," "estimate," "project," "potential," "continue" and similar expressions.
Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied, including, among others: the Company's ability to achieve expected revenue growth; the risk that preliminary second quarter results may differ from actual results following quarter-end close procedures; the Company's ability to successfully integrate Kare Pharmtech, Tollo Health, Datavault AI PharmacyChain™ functionality and other strategic initiatives; the Company's ability to launch the Health Lives Here app on the anticipated timeline or at all; the Company's ability to successfully develop, commercialize and scale EinsteinRx™ and PharmacyChain™-enabled capabilities; regulatory, reimbursement, data privacy, HIPAA, healthcare, FDA, FTC and other compliance risks; risks associated with medical food, dietary supplement, telehealth and AI-enabled healthcare offerings; the Company's ability to maintain and expand manufacturer, pharmacy, patient and strategic partner relationships; competitive conditions in the healthcare technology, pharmacy, telehealth and pharmaceutical distribution markets; the availability of capital; the Company's ability to maintain compliance with Nasdaq listing requirements; and the other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire